Abstract
The introduction of long-acting beta agonists (LABAs) was considered a major advance in bronchodilator therapy with evidence that their use led to improved lung function and quality of life. However, the use of LABAs has raised safety concerns, such as their potential to provoke severe asthma exacerbations (SAEs) and death. This systematic review of major findings discusses the safety controversy surrounding LABA therapy and provides background for the U.S. Food and Drug Administrations warnings concerning LABA use. Findings from large clinical trials and several meta-analyses are described and compared in terms of their implications for the safety of LABAs. Monotherapy LABA therapy in the treatment of asthma remains controversial and is not recommended by the most recent asthma management guidelines. Despite the existence of numerous published studies, we conclude that more well-designed research on this topic --- to determine whether LABAs are associated with SAEs, such as asthma-related hospitalizations, intubations, and emergency room visits, or death --- is required. Particularly needed is research that makes use of large, secondary longitudinal databases.
Keywords: Long-acting beta agonists (LABAs), asthma, SMART trial, safety controversy, African Americans, pediatric LABA use
Current Drug Safety
Title: Evaluating Safety of Long-Acting Beta Agonists (LABAs) in Patients with Asthma
Volume: 5 Issue: 3
Author(s): Boyang Bian, Christina M.L. Kelton, Patricia R. Wigle and Jeff J. Guo
Affiliation:
Keywords: Long-acting beta agonists (LABAs), asthma, SMART trial, safety controversy, African Americans, pediatric LABA use
Abstract: The introduction of long-acting beta agonists (LABAs) was considered a major advance in bronchodilator therapy with evidence that their use led to improved lung function and quality of life. However, the use of LABAs has raised safety concerns, such as their potential to provoke severe asthma exacerbations (SAEs) and death. This systematic review of major findings discusses the safety controversy surrounding LABA therapy and provides background for the U.S. Food and Drug Administrations warnings concerning LABA use. Findings from large clinical trials and several meta-analyses are described and compared in terms of their implications for the safety of LABAs. Monotherapy LABA therapy in the treatment of asthma remains controversial and is not recommended by the most recent asthma management guidelines. Despite the existence of numerous published studies, we conclude that more well-designed research on this topic --- to determine whether LABAs are associated with SAEs, such as asthma-related hospitalizations, intubations, and emergency room visits, or death --- is required. Particularly needed is research that makes use of large, secondary longitudinal databases.
Export Options
About this article
Cite this article as:
Bian Boyang, M.L. Kelton Christina, R. Wigle Patricia and J. Guo Jeff, Evaluating Safety of Long-Acting Beta Agonists (LABAs) in Patients with Asthma, Current Drug Safety 2010; 5 (3) . https://dx.doi.org/10.2174/157488610791698316
DOI https://dx.doi.org/10.2174/157488610791698316 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Managing Comorbidity in COPD: A Difficult Task
Current Drug Targets Heme Oxygenase-1: A Novel Therapeutic Target in Oxidative Tissue Injuries
Current Medicinal Chemistry Applications of Circadian Metabolomics
Current Metabolomics Interventions to Support Diabetes Self-Management: The Key Role of the Patient in Diabetes Care
Current Diabetes Reviews Thyroid Diseases During Pregnancy: Bibliometric Analysis of Scientific Publications
Endocrine, Metabolic & Immune Disorders - Drug Targets Cereal Exposures in the Infant Diet and Risk of Diabetes Autoimmunity in Children
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Clostridial Neurotoxins: Mode of Substrate Recognition and Novel Therapy Development
Current Protein & Peptide Science Lipoic Acid: A Novel Therapeutic Approach for Multiple Sclerosis and Other Chronic Inflammatory Diseases of the CNS
Endocrine, Metabolic & Immune Disorders - Drug Targets New Insights into the Regulation of Liver Inflammation and Oxidative Stress
Mini-Reviews in Medicinal Chemistry Neuroinflammation and Immunity: A New Pharmacological Target in Depression
CNS & Neurological Disorders - Drug Targets Pharma Emerging Market’s Scaning by Look and Feel of its Opportunities and Challenges
Applied Clinical Research, Clinical Trials and Regulatory Affairs Antidiabetic Oils
Current Diabetes Reviews Progress on the Screening and Analysis of Bioactive Compounds in Traditional Chinese Medicines by Biological Fingerprinting Analysis
Combinatorial Chemistry & High Throughput Screening Milestones in the Development of Chronic LPS-Induced Airway Disease
Current Respiratory Medicine Reviews Supercritical Fluid Particle Design for Poorly Water-soluble Drugs (Review)
Current Pharmaceutical Design Cross-talk of Signaling Pathways in the Pathogenesis of Allergic Asthma and Cataract
Protein & Peptide Letters Methotrexate-Induced Pneumonitis: Heterogeneity of Bronchoalveolar Lavage and Differences between Cancer and Rheumatoid Arthritis
Inflammation & Allergy - Drug Targets (Discontinued) Therapeutic Modulation of Coagulation and Fibrinolysis in Acute Lung Injury and the Acute Respiratory Distress Syndrome
Current Pharmaceutical Biotechnology Bacterial Conjunctivitis in Childhood: Etiology, Clinical Manifestations, Diagnosis, and Management
Recent Patents on Inflammation & Allergy Drug Discovery Metalloproteinases and Metalloproteinase Inhibitors in Age-Related Diseases
Current Pharmaceutical Design